Found: 16
Select item for more details and to access through your institution.
Hsp90 inhibition sensitizes DLBCL cells to cisplatin.
- Published in:
- 2022
- By:
- Publication type:
- journal article
SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Population pharmacokinetics of crenolanib in children and young adults with brain tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 4, p. 459, doi. 10.1007/s00280-022-04412-8
- By:
- Publication type:
- Article
Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 4, p. 469, doi. 10.1007/s00280-022-04410-w
- By:
- Publication type:
- Article
A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 4, p. 479, doi. 10.1007/s00280-022-04411-9
- By:
- Publication type:
- Article
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 4, p. 487, doi. 10.1007/s00280-022-04406-6
- By:
- Publication type:
- Article
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 4, p. 551, doi. 10.1007/s00280-022-04397-4
- By:
- Publication type:
- Article
Somatic nuclear auto-antigenic sperm protein sensitizes human breast cancer cells to 5-Fluorouracil.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice